Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
182
-
Total 13F shares, excl. options
-
59.9M
-
Shares change
-
+2.47M
-
Total reported value, excl. options
-
$1.73B
-
Value change
-
+$85.9M
-
Put/Call ratio
-
2.03
-
Number of buys
-
110
-
Number of sells
-
-73
-
Price
-
$28.93
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q1 2024
208 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q1 2024.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 182 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.9M shares
of 61.4M outstanding shares and own 97.58% of the company stock.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (5.74M shares), BlackRock Inc. (5.57M shares), RTW INVESTMENTS, LP (5.32M shares), BVF INC/IL (3.76M shares), STATE STREET CORP (3.27M shares), VANGUARD GROUP INC (3.19M shares), JOHNSON & JOHNSON (2.45M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.22M shares), MORGAN STANLEY (1.88M shares), and COWEN AND COMPANY, LLC (1.56M shares).
This table shows the top 182 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.